Learn about Mona El-Kalioby’s experience as a 2022 participant in IPC’s International Fellowship Program. In this exclusive interview, she shares how the program helped her personally and professionally.
The spread of COVID-19 in early 2020 brought many concerns and questions about COVID-19 and psoriasis. To help address these concerns dermatologists and researchers created PsoProtect and PsoProtectMe — two global registries aimed at understanding the impact of the pandemic on people with psoriasis. Co-directors of PsoProtect and PsoProtectMe, Catherine Smith and Satveer Mahil, speak about the data collection process and findings from these global registries.
The United States Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA) granted these designations based on the topline results from the EFFISAYIL™ 2 trial.
Learn about Juul van den Reek’s experience as a 2022 participant in IPC’s International Fellowship Program. In this exclusive interview, she shares how the program helped her expand her psoriasis research internationally and build valuable connections with experts in the field.
A host of factors is important to consider in the personalized treatment of psoriasis. It is advantageous if a treatment is effective in psoriasis and has beneficial effects on associated conditions. This recent literature publication has highlighted that apremilast, beyond its anti-psoriatic properties, positively impacts excessive alcohol consumption. Read the expert opinion of IPC Board Member Johann Gudjonsson, MD, PhD.
Introducing IPC’s newest Councilors for 2023: A cohort of global experts dedicated to improving patient care for psoriasis.
The International Psoriasis Council (IPC) has made significant progress in advancing psoriasis care and research worldwide in the first quarter of 2023. We invite you to watch our 2-minute video that highlights our key achievements.
The patient perspective has become even more important in the wake of the pandemic. Here’s how Clinica Dermacross is making it a priority.
Watch this short video to learn more about the International Psoriasis Council in less than a minute: Who we are, our vision, mission, history, and our community of psoriasis experts working to improve the health of people with psoriasis around the world.
The 2023 American Academy of Dermatology (AAD) Annual Meeting was held Thursday, March 16 – Tuesday, March 21, 2023, in New Orleans, LA, and is the largest dermatology meeting in the world, showcasing over 1,000 expert speakers and over 300 sessions. This report includes 13 summaries of talks focusing on psoriasis.
The European Commission has approved Sotyktu™ (deucravacitinib) in European Union.
The prognosis and maintenance of response after treatment discontinuation following remission lack proper characterization. Real-world data obtained from national registries may provide valuable insights into this clinical issue. Tiago Torres, MD, PhD, provides his expert opinion on a recent study that investigated epidemiological characteristics and disease markers during the first two years following cessation of biologic therapy due to remission in adult patients.
